Effects of contrast dose, delayed imaging, and magnetization transfer saturation on gadolinium-enhanced MR imaging of brain lesions

Journal of Magnetic Resonance Imaging

Volumn 7, Issue 1, 1997, Pages 14-22

  Mathews, Vincent P ^a,d   Caldemeyer, Karen S ^a   Ulmer, John L ^b   Nguyen, Hoang ^c   Yuh, William T C ^c  

^a INDIANA UNIVERSITY   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d University of Hospital   (United States)

Author keywords

Gadolinium chelates; MR imaging; Paramagnetic contrast agents

Indexed keywords

GADODIAMIDE; GADOLINIUM CHELATE; GADOLINIUM PENTETATE; GADOTERIC ACID; GADOTERIDOL;

BLOOD BRAIN BARRIER; BRAIN DISEASE; BRAIN INFARCTION; BRAIN INFECTION; BRAIN METASTASIS; BRAIN TUMOR; CONTRAST ENHANCEMENT; COST CONTROL; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW;

BLOOD-BRAIN BARRIER; BRAIN DISEASES; BRAIN NEOPLASMS; CEREBRAL INFARCTION; CLINICAL TRIALS; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GADOLINIUM; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; SENSITIVITY AND SPECIFICITY;

EID: 0031404150     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmri.1880070104     Document Type: Review

References (38)

1. Runge VM, Kirsch JE, Wells JW, Dunworth JN, Awh MH, Bittner DF. Magnetic resonance contrast agents in neuroimaging. Neuroimag Clin N Am 1994; 4:175-183.
2. Haustein J, Laniado M, Niendorf HP, et al. Triple-dose versus standard dose gadopentetate dimeglumine: a randomized study in 199 patients. Radiology 1993; 186:855-860.
3. Yuh WT, Fisher DJ, Engelken JD, et al. MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol. Radiology 1991; 180:485-491.
4. Niendorf HP, Laniado M, Semmler W, Schorner W, Felix R. Dose administration of gadolinium-DTPA in MR imaging of intracranial tumors. AJNR Am J Neuroradiol 1987; 8:803-815.
5. Runge VM, Kirsch JE, Burke VJ, et al. High-dose gadoteridol in MR imaging of intracranial neoplasms. J Magn Reson Imaging 1992; 2:9-18.
6. Runge VM, Gelblum DY, Pacetti ML, Carolan F, Heard G. Gd-HP-DO3A in clinical MR imaging of the brain. Radiology 1990; 177:393-400.
7. Yuh WT, Engelken JD, Muhonen MG, Mayr NA, Fisher DJ, Ehrhardt JC. Experience with high-dose gadolinium MR imaging in the evaluation of brain metastases. AJNR Am J Neuroradiol 1992; 13:335-345.
8. Yuh WT, Fisher DJ, Runge VM, et al. Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases. AJNR Am J Neuroradiol 1994; 15:1037-1051.
9. Runge VM, Wells JW, Nelson KL, Linville PM. MR imaging detection of cerebral metastases with a single injection of high-dose gadoteridol. J Magn Reson Imaging 1994; 4:669-673.
10. Runge VM, Wells JW, Williams NM. Magnetic resonance imaging of an experimental model of intracranial metastatic disease: a study of lesion detectability. Invest Radiol 1994; 29:1050-1056.
11. Yuh WT, Nguyen HD, Tali ET. Delineation of gliomas with various doses of MR contrast material. AJNR Am J Neuroradiol 1994; 15:983-989.
12. Runge VM, Kirsch JE, Wells JW, Dunworth JN, Woolfolk CE. Visualization of blood-brain barrier disruption on MR images of cats with acute cerebral infarction: value of administering a high dose of contrast material. AJR Am J Roentgenol 1994; 162:431-435.
13. Mathews VP, King JC, Elster AD, Hamilton CA. Cerebral infarction: effects of dose and magnetization transfer saturation at gadolinium-enhanced MR imaging. Radiology 1994; 190:547-552.
14. Runge VM, Wells JW, Williams NM, et al. Detectability of early brain meningitis with magnetic resonance imaging. Invest Radiol 1995; 30:464-495.
15. Runge VM, Wells JW, Kirsch JE. Magnetization transfer and high-dose contrast in early brain infection on magnetic resonance. Invest Radiol 1995; 30:135-143.
16. Haustein J, Laniado M, Niendorf HP, et al. Administration of gadopentetate dimeglumine in MR imaging of intracranial tumors: dosage and field strength. AJNR Am J Neuroradiol 1992; 1199-1206.
17. Mayr NA, Yuh WT, Muhonen MG, et al. Cost-effectiveness of high-dose MR contrast studies in the evaluation of brain metastases. AJNR Am J Neuroradiol 1994; 15:1053-1061.
18. Andreula CF, Burdi N, Carella A. CNS Cryptococcosis in AIDS: spectrum of MR findings. J Comput Assist Tomogr 1993; 17: 438-441.
19. Mathews VP, Monsein LH, Pardo CA, Bryan RN. Histologic abnormalities associated with gadolinium enhancement on MR in the initial hours of experimental cerebral infarction. AJNR Am J Neuroradiol 1994; 15:573-579.
20. Asato R, Okumura R, Konishi J. "Fogging effect" in MR of cerebral infarct. J Comput Assist Tomogr 1991; 15:160-162.
21. Schorner W, Laniado M, Niendorf HP, Schubert C, Felix R. Time-dependent changes in image contrast in brain tumors after gadolinium-DTPA. AJNR Am J Neuroradiol 1986; 7:1013-1020.
22. Graif M, Bydder GM, Steiner RE, Niendorf P, Thomas DG, Young IR. Contrast-enhanced MR imaging of malignant brain tumors. AJNR Am J Neuroradiol 1985; 6:855-862.
23. Virapongse C, Mancuso A, Quisling R. Human brain infarcts: Gd-DTPA-enhanced MR imaging. Radiology 1986; 161:785-794.
24. Balaban RS, Ceckler TL. Magnetization transfer contrast in magnetic resonance imaging. Magn Reson Q 1992; 8:116-137.
25. Tanttu JI, Sepponen RE, Lipton MJ, Kuusela T. Synergistic enhancement of MRI with Gd-DTPA and magnetization transfer. J Comput Assist Tomogr 1992; 16:19-24.
26. Elster AD, Mathews VP, King JC, Hamilton C. Improved detection of gadolinium enhancement using magnetization transfer imaging. Neuroimag Clin N Am 1994; 4:185-192.
27. Ulmer JL, Mathews VP, Hamilton CA, Elster AD, Moran PR. Magnetization transfer or spin-lock? an investigation of off-resonance saturation pulse imaging using varying frequency offsets. AJNR Am J Neuroradiol 1996; 17:805-819.
28. Moran PR, Hamilton CA. Near-resonance spin-lock contrast. Magn Reson Imaging 1995; 13:837-846.
29. Finelli DA, Hurst GC, Gullapali RP, Bellon EM. Improved contrast of enhancing brain lesions on postgadolinium, T1-weighted spin-echo images with use of magnetization transfer. Radiology 1994; 190:553-559.
30. Finelli DA, Hurst GC, Gullapali RP. Magnetization transfer doubles the contrast to noise ratio of enhancing lesion on 3D RF-spoiled GRE images of the brain. Radiology 1995; 197(P):409.
31. Trattnig S, Kontaxis G, Breitenseher MJ, Helbich T, Heinz-Peer G, Imhof H. Increase sensitivity to contrast enhancement of brain tumors with a T1-weighted 3D GRE sequence with use of MTC prepulses. Radiology 1995; 197(P):410.
32. Mehrta RC, Pike GB, Haros SP, Enzmann DR. Central nervous system tumor, infection, and infarction: detection with gadolinium-enhanced magnetization transfer MR imaging. Radiology 1995; 195:41-46.
33. Kurki TJI, Niemi PT, Lundbom N. Gadolinium-enhanced magnetization transfer contrast imaging of intracranial tumors. J Magn Reson Imaging 1992; 2:401-406.
34. Burke JW, Mathews VP, McLean FM, Ulmer JL, Davis SB. Improved MR detection of enhancing CNS metastases using magnetization transfer saturation. In: Proceedings of the 33rd annual meeting (in Chicago, IL) of the American Society of Neuroradiology. 1995; 110.
35. Burke JW, Mathews VP, Ulmer JL, Davis SB, McLean FM. Contrast-enhanced magnetization transfer saturation imaging improves MR detection of herpes simplex encephalitis. AJNR Am J Neuroradiol 1996; 17:773-776.
36. Mathews VP, Burke JW, Davis SB, McLean FM, Ulmer JL. Enhanced T1-weighted images with magnetization transfer saturation improves characterization of intracranial masses in patients with AIDS. In: Proceedings of the 33rd annual meeting (in Chicago, IL) of the American Society of Neuroradiology. 1995; 106.
37. Mathews VP, Ulmer JL, Hamilton CA, Reboussin DM, King JC, Elster AD. Combined effects of magnetization transfer and gadolinium in cranial MR imaging and MR angiography. AJR Am J Roentgenol 1995; 164:169-172.
38. Mathews VP, Ulmer JL, Davis SB, McLean FM, Dipersio DA, Elster AD. Cranial magnetization transfer images after half-dose Gd-DTPA compared with T1-weighted images after full-dose Gd-DTPA. Radiology 1995; 197(P):409.